Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvotech Could Upend Expectations For US Humira Biosimilars

Founder And Chairman Robert Wessman Discusses Firm’s Adalimumab Prospects

Executive Summary

In the second part of an exclusive two-part interview with Generics Bulletin, Alvotech founder and chairman Robert Wessman sets out the firm’s expectations for its rival to Humira, as Alvotech continues to battle AbbVie in US litigation over its higher-strength adalimumab biosimilar.

You may also be interested in...



Alvotech’s Ustekinumab Passes Safety And Efficacy Milestone

Alvotech has announced success in its confirmatory clinical safety and efficacy study for its AVT04 ustekinumab candidate, a proposed biosimilar to Stelara.

Alvotech Reveals Positive Data For Stelara Rival

Alvotech has reported positive results from a study for its AVT04 proposed biosimilar ustekinumab rival to Stelara. The news comes ahead of a key vote on Alvotech’s SPAC merger with Oaktree Capital Management that will take the company public.

Amgen’s Stelara Biosimilar Produces Positive Phase III Results

Amgen has reported positive preliminary results from a Phase III study for its ABP 654 proposed ustekinumab biosimilar rival to Stelara, for which the firm also intends to pursue an interchangeability designation.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151615

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel